Q-omics provides the consensus-scored LINC00637 profile across patient tissues and cancer cell-line models. LINC00637 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC00637 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, LINC00637 RNA expression shows 12,209 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, LIHC, and THYM as cancer lineages where LINC00637 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00637 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00637 survival associations across molecular data types. LINC00637 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00637 RNA expression–survival associations across cancer types. High LINC00637 expression shows unfavorable associations in SKCM and KIRP, but favorable associations in LUAD, ACC, HNSC and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC00637 RNA expression.
This table summarizes LINC00637 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00637. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00637 shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, LUSC, HNSC and PRAD. The LIHC box plot shows higher LINC00637 RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p < 0.001).
This table shows molecular features associated with LINC00637 in patient tissues and cancer cell lines. In patient samples, LINC00637 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
